Loading
Ovarian Cancer Diagnosis and Treatment / Ovarian Function and Disorders · Journal article
Diabetology & Metabolic Syndrome · August 6, 2026
Early or partial results. Treat as a signal, not a conclusion.
This study characterizes three rat models of PMOS—letrozole (Let), letrozole plus high-fat diet (Let+HFD), and DHEA—by comparing their endocrine, hormonal, and metabolic profiles to those of 110 BMI-stratified human PMOS patients. Each model reproduced hyperandrogenism and ovarian follicular abnormalities but differed in metabolic severity: the Let+HFD model showed more pronounced obesity and dyslipidemia, whereas the DHEA model was marked by hyperandrogenism with hyperuricemia. The finding suggests that model selection should be tailored to the specific research question rather than assuming any single model captures the full heterogeneity of clinical PMOS.
Comparative animal model study with parallel clinical cohort (observational). Clinical: BMI-stratified PMOS patients (obese and non-obese phenotypes) and healthy controls. Animal: Female Sprague-Dawley rats at two different starting ages (8-week-old for Let/Let+HFD, 3-week-old for DHEA).. Intervention: Three PMOS induction protocols: Letrozole (Let), Letrozole plus high-fat diet (Let+HFD), and dehydroepiandrosterone (DHEA) in separate rat cohorts.. Compared with: Vehicle-treated control groups for each animal model; healthy control subjects in clinical cohort..
Clinical PMOS cohort exhibited hyperandrogenism, insulin resistance, and increased antral follicle count (AFC), with metabolic disturbances more pronounced in obese phenotype All three rat models reproduced hyperandrogenism and ovarian follicular abnormalities Let model reflected reproductive endocrine dysfunction predominantly
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This work provides a comparative framework for selecting appropriate rat models of PCOS-like phenotypes for specific research aims. Clinicians and researchers should recognize that no single animal model fully replicates the heterogeneity of human PMOS; model choice should align with whether the study emphasizes reproductive endocrine dysfunction, metabolic impairment, or androgenic features.
Systematic comparison of three rat models against clinical PMOS features, but uncontrolled animal work with small per-group samples (n=8) and no between-model statistical testing reported; provides descriptive phenotypic characterization to guide model selection rather than a testable clinical or mechanistic finding.
As stated by the source record.
Quoted from the source exactly as published.
This work provides a comparative framework for selecting appropriate rat models of PCOS-like phenotypes for specific research aims. Clinicians and researchers should recognize that no single animal model fully replicates the heterogeneity of human PMOS; model choice should align with whether the study emphasizes reproductive endocrine dysfunction, metabolic impairment, or androgenic features.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Polyendocrine metabolic ovarian syndrome (PMOS) is a highly heterogeneous disorder characterized by diverse phenotypes, including obesity and hyperandrogenism. However, the extent to which current animal models replicate these clinical features remains poorly defined. This study systematically compared the endocrine and metabolic fidelity of different PMOS models to provide a basis for model selection in targeted research. A clinical cohort of 110 BMI-stratified PMOS patients and 100 healthy controls was recruited for endocrine and metabolic profiling. Concurrently, three PMOS rat models were established using Letrozole (Let), letrozole plus high-fat diet (Let + HFD), or dehydroepiandrosterone (DHEA). Eight-week-old female rats were used to establish the Let and Let + HFD models and their corresponding control groups ( n = 8 per group), whereas 3-week-old female rats were used to establish the DHEA model and its corresponding control group ( n = 8 per group). The phenotypic fidelity of these models was systematically evaluated by comparing body weight, hormonal levels, ovarian morphological changes, and metabolic markers with clinical features of PMOS. Patients with PMOS exhibited typical endocrine and metabolic abnormalities, including hyperandrogenism, insulin resistance, and increased antral follicle count (AFC), with metabolic disturbances being more pronounced in the obese phenotype. All three animal models reproduced the key features of PMOS, including hyperandrogenism and ovarian follicular abnormalities, but displayed distinct phenotypic characteristics. The Let model predominantly reflected reproductive endocrine dysfunction, the Let + HFD model showed more severe metabolic impairment characterized by obesity and dyslipidemia, and the DHEA model was mainly characterized by hyperandrogenism accompanied by hyperuricemia. Different PMOS animal models reflect distinct endocrine and metabolic features rather than the full clinical heterogeneity of PMOS. Appropriate model selection should therefore be guided by the specific research objective.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.